- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Vlad Hogenhuis, Merck
S
Vlad Hogenhuis
General Manager for Neuroscience, Dermatology, and Ophthalmology, Merck
RECRUITED BY: Merck CEO Roy Vagelos
EXECS NEED: The courage to do what's right
I got a call from Dr. Vagelos, with the opportunity to be part of his mission" is how Vlad Hogenhuis, MD, introduces his 14-year career at Merck. Hogenhuis was getting a Wharton MBA at the time, but he has pharma in his blood. Born in the Netherlands to a long line of physicians—his father developed a migraine drug—he practiced medicine for four years before deciding to jump to industry.
Vlad Hogenhuis
He's climbed the Merck ladder by crossing from managing to managed care to licensing to R&D strategy. "I had a broad view early on," he says. Under CEO Dick Clark's new model integrating clinical and commercial, he directs both the late-stage pipeline and global marketing for a $1.7 billion three-disease franchise. "I have end-to-end accountability," he says. "There's full alignment of what the sales force does and what we do in marketing and even in Phase III."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
